As a sub-analysis of the ERSPC trial, the Göteborg PCa screening trial reported that PCa mortality was reduced almost by 50% over 14 years through PSA at median age of 56 years and screening intervals of two years [8]. The gene discussed is KLK3; the disease is posterior cortical atrophy.